This Blog AMICOR is a communication instrument of a group of friends primarily interested in health promotion, with a focus on cardiovascular diseases prevention.
To contact send a message to
Breakthrough findings demonstrate a possible target and potential drug treatment to restore memory loss and extend life span in mice with neurodegeneration.
An international team of scientists has announced a new advance in the fight against Alzheimer's disease by identifying a new drug target for not only improving symptoms of brain degeneration - but also to extend the life-span of the terminally ill mice.
The four-year study by Medical Research Council (MRC) scientists based at the MRC Toxicology Unit at the University of Leicester is published in the Journal of Clinical Investigation. The study was led by Professor Andrew Tobin alongside colleagues from pharmaceutical company Eli Lilly and Company and the Monash Institute for Pharmaceutical Sciences in Australia. The project was also partly supported by the Wellcome Trust.
Corresponding author Professor Tobin, who alongside the lead researcher Dr Sophie Bradley has since moved from the University of Leicester to the University of Glasgow, said: "The paper describes drug-like molecules that can restore memory loss and slow progression of prion neurodegenerative disease in a manner that relates to the potential of these drugs in human Alzheimer's disease.